Subscribe to the Antiviral InteliStrat Database
You need to be a member to get access to the database. Many options are available for subscribing along with subscription rates, as described on the Services page.
Below is a sample of information available upon subscribing to the database. This includes detailed product files that can be visualized by clicking on the product's name appearing in the grid.
Contact us at firstname.lastname@example.org for a free TRIAL!
Log into your account
|Sponsor(s)||Product||Type of product||Mode of action||Viral family||Virus||Status-1||Status-2|
|Sanofi Pasteur / Sanofi Aventis (global presence)||ChimeriVax-Dengue
ChimeriVax Dengue; CYD Dengue
|Vaccine||Recombinant, viral expr vector||Flaviviridae||Dengue virus||Phase III||Evaluated as tetravalent vaccine; Development initiated at Acambis|
|GlaxoSmithKline (GSK; global presence)||Retrovir®
zidovudine; azidothymidine; AZT; BW A509U; Zydowin
|Inhibitor||NRTI||Retroviridae||HIV (Human Immunodeficiency virus)||Market||Approved for market in US (Mar. 19, 1987) and other markets|
|Pharmacor (acquired by Procyon/Ambrilia Biopharma; Canada)||P-1946||Inhibitor||PI||Retroviridae||HIV (Human Immunodeficiency virus)||Preclinical||Lead compound|
|Novartis (global presence)||Focetria®
Focetria® A(H1N1); Focetria A(H1N1); Focetria A/H1N1; Influenza A (H1N1) 2009 Monovalent Vaccine
|Vaccine||Non-recombinant protein vaccine||Orthomyxoviridae||Swine Influenza virus||Market||Approved by EMEA for distribution in EU (Sept. 29, 2009) under control of health authorities and governments; WHO-Prequalification status; See Remarks|